In drug discovery, compound promiscuity and selectivity refers to the ability of drug compounds to bind to several different- (promiscuous) or only one main target (selective). An important distinction here is that promiscuity is defined as specific interactions with multiple biological targets (polypharmacology) rather than a number of non-specific targets. At first glance, you might expect drugs to be designed to be as selective as possible, only hitting one biological target necessary to treat the disease and therefore reduce the chance of any side effects. This paradigm of single-target specificity has been challenged over the past two decades. Even between scientists in the drug discovery field, compound promiscuity is still a controversial topic. The field has increasingly paid attention to the topic of polypharmacology and studies have shown many pharmaceutically relevant compounds, including approved drugs to derive their biological activity from polypharmacology [1-3].
Continue readingCategory Archives: Publications
The Coronavirus Antibody Database (CoV-AbDab)
We are happy to announce the release of CoV-AbDab, our database tracking all coronavirus binding antibodies and nanobodies with molecular-level metadata. The database can be searched and downloaded here: http://opig.stats.ox.ac.uk/webapps/coronavirus
Continue readingDeLinker – Deep Generative Models for 3D Linker Design
*** Disclaimer: This blog post represents some shameless self-promotion. ***
I am delighted to announce that our most recent work, DeLinker, was recently published in the Journal of Chemical Information and Modeling (link).
TCRBuilder: Multi-state T-cell receptor structure prediction
Hello friends of OPIG,
From my last blopig blog post [link: https://www.blopig.com/blog/2019/10/comparative-analysis-of-the-cdr-loops-of-antigen-receptors/], I summarised our findings that TCR CDRs are more flexible than their antibody counterparts. Because of this observation, we believe that it is more appropriate to represent TCR binding sites using an ensemble of conformations.
Continue readingState of the art in AI for drug discovery: more wet-lab please
The reception of ML approaches for the drug discovery pipeline, especially when focused on the hit to lead optimization process, has been rather skeptical by the medchem community. One of the main drivers for that is the way many ML publications benchmark their models: Historic datasets are split into two parts, with the larger part used to train and the smaller to test ML models. In order to standardize that validation process, computational chemists have constructed widely used benchmark datasets such as the DUD-E set, which is commonly used as a standard for protein-ligand binding classification tasks. Common criticism from medicinal chemists centers on the main problem associated with benchmark datasets: the absence of direct lab validation.
Continue readingThe evolution of contact prediction – a new paper
I’m so pleased to be able to write about our work on The evolution of contact prediction: evidence that contact selection in statistical contact prediction is changing (Bioinformatics btz816). Contact prediction – the prediction of parts of the amino-acid chain that are close together – has been critical to improving the ability of scientists to predict protein structures over the last decade. Here we look at the properties of these predictions, and what that might mean for their use.
The paper begins with a question. If contact prediction methods are based on statistical properties of sequence alignments, and those alignments are generated in the presence of ecological and physical constraints, what effect do the physical constraints have on the statistical properties of real sequence alignments? More concisely: when we predict contacts, do we predict particularly important contacts?
Continue readingBOKEI: Bayesian Optimization Using Knowledge of Correlated Torsions and Expected Improvement for Conformer Generation
In previous blog post, we introduced the idea of Bayesian optimization and its application in finding the lowest energy conformation of given molecule[1]. Here, we extend this approach to incorporate the knowledge of correlated torsion and accelerate the search.
Continue readingModelling Conformational Flexibility of Kinases in Inactive States
I would like to shamelessly advertise my master thesis project which just got published in Proteins. Keep on reading if you are interested in kinases and/or systematic modelling of protein families.
Continue readingFinding the lowest energy conformation of given molecule!
Generating low-energy molecular conformers is important for many areas of computational chemistry, molecular modeling and cheminformatics. Many tools have been developed to generate conformers, including BALLOON (1), Confab (2), FROG2 (3), MOE (4), OMEGA (5) and RDKit (6). The search algorithm implemented in these tools can be broadly classified as either systematic or stochastic. These algorithms primarily focus on generating geometrically diverse low-energy conformers. Here, we are interested in finding lowest energy conformation of a molecule instead of achieving geometric diversity and Bayesian optimization is used to find the lowest energy conformation (7). Continue reading
What can you do with the OPIG Antibody Suite?
OPIG has now developed a whole range of tools for antibody analysis. I thought it might be helpful to summarise all the different tools we are maintaining (some of which are brand new, and some are not hosted at opig.stats), and what they are useful for.
Immunoglobulin Gene Sequencing (Ig-Seq/NGS) Data Analysis
1. OAS
Link: http://antibodymap.org/
Required Input: N/A (Database)
Paper: http://www.jimmunol.org/content/201/8/2502
OAS (Observed Antibody Space) is a quality-filtered, consistently-annotated database of all of the publicly available next generation sequencing (NGS) data of antibodies. Here you can: